On this page
- 1How Much Salt Is Too Much With IgA Nephropathy?
- 2How Much Protein to Eat With IgA Nephropathy
- 3Blood Pressure Targets for IgA Nephropathy
- 4Pregnancy With IgA Nephropathy
- 5Why Urine Can Turn Red or Brown After a Cold With IgA Nephropathy
- 6Exercise, Smoking and Weight With IgA Nephropathy
- 7Pain Relievers, Supplements and Fish Oil With IgA Nephropathy
- 8Common questions
- Sources
Blood pressure is one number that can be checked day to day. The KDIGO 2025 guideline for IgA nephropathy sets a target of 120/70 or lower. Its broader blood pressure guideline suggests home readings alongside office ones.
Most of life with IgA nephropathy happens between nephrology visits, at the dinner table, at the pharmacy and in the days after a bad cold. The 2025 KDIGO guideline for IgA nephropathy counts several everyday steps as part of treatment. They are less than 2 grams of sodium a day, stopping smoking and vaping, weight control and endurance exercise.
This guide sets out what that guideline, KDIGO's broader 2024 chronic kidney disease guideline and the FDA labels for IgA nephropathy drugs say about each part of daily life. None of it replaces a nephrologist or a renal dietitian, who can fit the numbers to one person's kidneys, weight and medicines.
How Much Salt Is Too Much With IgA Nephropathy?
The KDIGO 2025 guideline for IgA nephropathy sets sodium below 2 grams a day. KDIGO's 2024 chronic kidney disease guideline and its patient summary put that as less than 5 grams of salt. Table salt is 40% sodium, according to the CDC.
Set side by side, those numbers mean the average American eats about 1.7 times the KDIGO limit for people with IgA nephropathy. Trial Friend divided the FDA's 3,400mg average by KDIGO's 2,000mg limit, both checked November 19, 2026. Even the general US limit of 2,300mg sits about 15% above the kidney guideline.
Salt substitutes are not a simple swap. KDIGO's 2021 blood pressure guideline notes that potassium-based substitutes may not suit people with advanced chronic kidney disease, so that choice is worth checking with the care team.
How Much Protein to Eat With IgA Nephropathy
The KDIGO 2025 IgA nephropathy guideline has no protein rule of its own, so the advice comes from KDIGO's 2024 chronic kidney disease guideline. It suggests 0.8 grams of protein per kilogram of body weight a day for adults with CKD stages G3 to G5. For adults with CKD at risk of progression, it advises avoiding more than 1.3 grams per kilogram a day.
| Guideline | Grams per kilogram a day | Grams a day at 70kg |
|---|---|---|
| KDIGO 2024 suggestion for CKD stages G3 to G5 | 0.8 | 56g |
| KDIGO 2024 upper limit for CKD at risk of progression | 1.3 | 91g |
| Dietary Guidelines for Americans 2025-2030, general target | 1.2-1.6 | 84-112g |
The general US target and the kidney guideline point in different directions here. The top of the Dietary Guidelines range is above KDIGO's upper limit for people whose kidney disease is at risk of getting worse. KDIGO's patient summary says 1 ounce of meat or 1 egg holds about 6-8 grams of protein, which helps when comparing a meal with a daily number.
Blood Pressure Targets for IgA Nephropathy
The KDIGO 2025 IgA nephropathy guideline sets a blood pressure target of 120/70 or lower. KDIGO's 2021 blood pressure guideline for chronic kidney disease gives only a top number, a systolic target under 120 when tolerated, measured with a standardized office reading.
That 2021 guideline warns that using the under-120 target with readings that were not taken the standardized way is potentially hazardous. It suggests home or 24-hour monitoring alongside office readings, though it says the right target for home readings is unknown. KDIGO's 2024 chronic kidney disease guideline allows less intensive treatment for people with frailty, a high risk of falls, very limited life expectancy or dizziness on standing.
Medicines are part of the same picture. KDIGO recommends an ACE inhibitor or ARB at the highest dose a person tolerates for everyone with IgA nephropathy, with exceptions such as low blood pressure or high potassium. Filspari is not given together with an ACE inhibitor or ARB.
Pregnancy With IgA Nephropathy
The KDIGO 2025 guideline says all women with IgA nephropathy who could become pregnant should be offered counseling before conception. It says that counseling should include a discussion of stopping certain medicines and of switching to other blood pressure medicines before conception. The medicines it names are ACE inhibitors and ARBs, SGLT2 inhibitors, sparsentan, Nefecon and steroids.
Those decisions belong with the nephrologist and an obstetrician, and KDIGO's 2021 glomerular disease guideline asks the 2 to coordinate care, ideally before pregnancy. For breastfeeding, the 2025 guideline says SGLT2 inhibitors and sparsentan should not be used, and enalapril can be used if a blood pressure medicine of that kind is needed.
| Medicine | What the label says |
|---|---|
| ACE inhibitors and ARBs | A boxed warning that they can injure or kill a developing fetus, and that prescribers should stop them as soon as possible when pregnancy is detected |
| Filspari (sparsentan) | A boxed warning for harm to an unborn baby. Pregnancy is ruled out before starting, and effective birth control is used before, during and for 2 weeks after treatment |
| Vanrafia (atrasentan) | A boxed warning that it may cause major birth defects, based on animal data, with the same birth control rule as Filspari |
| Tarpeyo (budesonide) | No pregnancy boxed warning. Oral budesonide data have not shown a drug-related risk of major birth defects, and exposed newborns can have low adrenal function |
| Fabhalta (iptacopan) | Use in pregnancy may be considered after weighing the risks and benefits |
| Voyxact (sibeprenlimab) | No data from pregnant women. A monkey study showed no harm to development, and antibodies of this kind cross the placenta more in the second and third trimesters |
| Trutakna (atacicept) | Too little data to judge the risk, and it may suppress the immune system of an infant exposed before birth. Animal studies showed no birth defects |
| Ultomiris (ravulizumab) | No data from pregnant women; animal studies of a similar molecule showed developmental problems, and a pregnancy registry collects outcomes |
Pregnancy does not appear to speed up IgA nephropathy in women with preserved kidney function, according to a 2016 review of 376 pregnancies. It found no rise in kidney events compared with women who did not become pregnant. It reported 12.2% infant loss, 8.5% preterm birth and 7.3% preeclampsia, and its authors concluded complications are more likely (Liu et al., 2016).
Kidney function at the start matters. In a 2017 Chinese study of 413 women, pregnancy was linked to faster eGFR loss only in those who started at CKD stage 3 or 4. They lost 7.44mL/min a year, against 3.90 in similar women who did not become pregnant. No such link appeared at stages 1 and 2 (Su et al., 2017).
Why Urine Can Turn Red or Brown After a Cold With IgA Nephropathy
NIDDK says visible blood can turn the urine pink or cola-colored, and that the first signs of IgA nephropathy can follow a cold or sore throat. A 2024 review puts these episodes 1 to 2 days after a respiratory infection begins (Gomes et al., 2024).
Trial Friend set the timing for IgA nephropathy from a 2024 review beside the CDC's timing for post-streptococcal glomerulonephritis, checked November 19, 2026. That is a different kidney inflammation that follows strep infections, and the CDC puts it about 10 days to 3 weeks after the infection.
These episodes can come with a short-term drop in kidney function. KDIGO's 2025 guideline says acute kidney injury can accompany heavy visible blood, commonly with an upper respiratory infection. It says a repeat biopsy should be considered if kidney function does not improve within 2 weeks after the bleeding stops.
Most episodes end with kidney function recovering, but not all. A 2007 Spanish study looked at 36 episodes of kidney injury with visible blood. Kidney function did not return to its earlier level after 25% of them. That was more likely when the visible blood lasted longer than 10 days or the person was over 50 (Gutiérrez et al., 2007).
Repeated episodes are not necessarily a bad sign over the long term. A 2014 Chinese study of 1,155 patients found 20-year kidney survival of 91% in people with repeated episodes, against 57% in people who never had one (Le et al., 2014). That is an association, and people with repeated episodes were also younger, with less protein and better kidney function at biopsy.
Exercise, Smoking and Weight With IgA Nephropathy
The 2024 KDIGO chronic kidney disease guideline recommends at least 150 minutes a week of moderate-intensity physical activity, or as much as a person's heart and health allow. It also advises avoiding a sedentary lifestyle. The 2025 IgA nephropathy guideline lists endurance exercise among its lifestyle measures.
Smoking has been tied to faster loss of kidney function in IgA nephropathy. A 2010 Japanese study of 971 patients found current smokers had about twice the risk of a 50% rise in blood creatinine, a sign of lost kidney function. The risk rose about 21% with each 10 cigarettes a day (Yamamoto et al., 2010). The 2025 guideline lists stopping smoking and vaping among its lifestyle measures. An older French study of 162 patients linked a body mass index of 25 or more to higher rates of high blood pressure and kidney failure (Bonnet et al., 2001).
Pain Relievers, Supplements and Fish Oil With IgA Nephropathy
KDIGO's 2024 chronic kidney disease guideline says people with kidney disease may be more sensitive to medicines that harm the kidneys. It advises reviewing and limiting over-the-counter medicines and dietary or herbal remedies that may be harmful in kidney disease. NIDDK says NSAID pain relievers such as ibuprofen and naproxen can damage the kidneys if taken for a long time, or when someone is dehydrated. Which pain reliever suits someone is a question for the care team.
Fish oil comes up often. The 2025 IgA nephropathy guideline lists it among treatments that failed to show a consistent benefit and marks it as not recommended. It says people who wish to take it should be told the dose and formulation used in the trials that reported a benefit.
Everyday IgA Nephropathy Questions
How much sodium should I eat a day with IgA nephropathy?
The KDIGO 2025 IgA nephropathy guideline sets sodium below 2,000mg a day, which is about 5 grams of salt. One teaspoon of salt holds about 2,300mg of sodium according to the FDA, or about 2,400mg according to the CDC.
Is it safe to get pregnant with IgA nephropathy?
A 2016 review of 376 pregnancies found kidney outcomes were unchanged when kidney function was preserved. FDA labels for IgA nephropathy drugs say the disease in pregnancy is linked to higher rates of preeclampsia and preterm delivery. The KDIGO 2025 guideline asks that every woman who could become pregnant be offered counseling before conception, including on stopping some medicines.
Why does my urine turn brown after a sore throat?
In IgA nephropathy, an infection can trigger a flare that sends blood into the urine within a day or 2, turning it pink, red or cola-colored. KDIGO says these episodes can come with a short-term drop in kidney function, so it is worth telling the nephrologist when one happens.
Can I take ibuprofen with IgA nephropathy?
That is a question for the nephrologist, because KDIGO's 2024 guideline advises limiting over-the-counter medicines that may harm the kidneys. NIDDK says NSAIDs such as ibuprofen can damage the kidneys with long use or when taken while dehydrated.
Does fish oil help IgA nephropathy?
The KDIGO 2025 guideline lists fish oil among treatments that failed to show a consistent benefit in IgA nephropathy and marks it as not recommended. It says anyone who wishes to take it should be told the dose and formulation used in the trials that reported a benefit.
Free email alert
Get IgA nephropathy trial and FDA news by email
One email when a new IgA nephropathy trial opens or the FDA acts on a IgA nephropathy treatment. Unsubscribe anytime.
You'll get trial alerts and disease updates for IgA Nephropathy, and you can turn either off anytime. We never share your email. Privacy policy
Trial Friend articles on IgA nephropathy
November 9, 2026 · 13 min readWhat Parents and Caregivers of a Child With IgA Nephropathy Should Know When Every Approved Drug Is Labeled for AdultsNone of the 7 FDA-approved IgA nephropathy drugs is approved for children, yet 6 of them are now in company studies registered to enroll kids. What the first sign usually looks like, how the childhood disease differs from the adult one, what the 2025 IPNA pediatric recommendations say, and which studies take children.
September 29, 2026 · 13 min readAtacicept vs Povetacicept for IgA Nephropathy Before the FDA Decision on November 30thAtacicept and povetacicept block the same 2 immune signals in IgA nephropathy. Atacicept is approved as Trutakna and now has 2-year kidney data. Povetacicept faces an FDA decision on November 30th and would be injected 13 times a year instead of 52. A side-by-side table, the trial results, what an independent review found, what patients told the FDA, and 7 real-world situations.
September 16, 2026 · 10 min read7 Approved Drugs for IgA Nephropathy and What Their Labels Actually PromiseIgA nephropathy went from zero approved drugs to 7 in under 5 years, most recently Ultomiris. Only 3 have proven on their labels that they protect kidney function. The other 4 are approved on a urine protein number and still owe that proof. Here is the difference and why it matters to you.
March 31, 2026 · 8 min readIgA Nephropathy Went From Zero Approved Drugs to 7 in Under 5 Years, and Where Fabhalta FitsIgA nephropathy had no FDA-approved treatment before December 2021 and has 7 today. This guide lists them, explains Fabhalta's 2-year NEJM results showing 49.3% slower kidney function decline than placebo, and puts Biohaven's early BHV-1400 data in context.
Sources
Trial Friend checked this guide against these sources on November 19, 2026. It explains what kidney guidelines, FDA labels and published studies say. It is not medical advice or a reason to start, stop or change a medicine.
- KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney International 2025;108(4S):S1-S71, KDIGO, 2025-10.
- Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2024;105:684-701, KDIGO, 2024-04.
- Top 10 Takeaways for People Living with CKD. KDIGO, 2025-01.
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International 2021;99(3S):S1-S87, KDIGO, 2021-03.
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International 2021;100(4S):S1-S276, KDIGO, 2021-10.
- Sodium in Your Diet. U.S. Food and Drug Administration, 2024-03-05.
- About Sodium and Health. Centers for Disease Control and Prevention, 2026-06-29.
- Dietary Guidelines for Americans 2025-2030. U.S. Department of Agriculture and Department of Health and Human Services, 2026-01.
- A Systematic Review and Meta-Analysis of Kidney and Pregnancy Outcomes in IgA Nephropathy. American Journal of Nephrology 2016;44:187-193 (Liu Y et al.), 2016.
- Pregnancy and Kidney Outcomes in Patients With IgA Nephropathy: A Cohort Study. American Journal of Kidney Diseases 2017;70:262-269 (Su X et al.), 2017.
- IgA Nephropathy. National Institute of Diabetes and Digestive and Kidney Diseases, 2022-09.
- Clinical Guidelines for Post-Streptococcal Glomerulonephritis. Centers for Disease Control and Prevention, 2025-08-05.
- Emerging perspectives in the management of IgA nephropathy: a comprehensive review. Porto Biomedical Journal 2024 (Gomes AM et al.), 2024.
- Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clinical Journal of the American Society of Nephrology 2007;2:51-57 (Gutiérrez E et al.), 2007.
- Long-term outcome of IgA nephropathy patients with recurrent macroscopic hematuria. American Journal of Nephrology 2014;40:43-50 (Le W et al.), 2014.
- Cigarette smoking and progression of IgA nephropathy. American Journal of Kidney Diseases 2010;56:313-324 (Yamamoto R et al.), 2010.
- Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. American Journal of Kidney Diseases 2001;37:720-727 (Bonnet F et al.), 2001.
- Keeping Kidneys Safe. National Institute of Diabetes and Digestive and Kidney Diseases, 2018-06.
- FDA drug labels for ACE inhibitors, ARBs, Filspari, Vanrafia, Tarpeyo, Fabhalta, Voyxact, Trutakna and Ultomiris. U.S. Food and Drug Administration, openFDA, 2026-11-19.
